Mave Health Raises $2.1M in Seed Funding to Launch Neurotech Wearable

Mave Health just stepped into a space most people tiptoe around and did it with a headset that weighs less than your morning indecision. $2.1M in seed funding, led by Blume Ventures with Stanford Angels, Dhaval Shroff, and Raymond Russell backing the play, and suddenly focus, mood, and stress are no longer abstract conversations, they are productized in 20-minute sessions. Not bad for a company founded in 2023 that decided the brain deserved the same daily optimization treatment as your calendar.

Big nod to Dhawal Jain, Founder and CEO, alongside Aman Kumar, Co-founder and CTO, and Jai Sharma, Co-founder driving the narrative. Three college batchmates who took a deeply human origin story and translated it into something tangible. Not therapy as a concept, not another app fighting for screen time, but a wearable built on transcranial direct current stimulation, a technology that has been studied for over 25 years and is now finding its way into everyday hands without the friction of clinical gatekeeping.

They ran a 500+ user beta before asking the market for belief, and the data came back talking. A strong majority of users reported meaningful improvements in productivity, mood, and stress reduction. That is the kind of signal investors listen to when deciding whether this is science fiction or something closer to infrastructure for the modern knowledge worker.

San Francisco and Bengaluru in the same sentence is not geography, it is strategy. Build where engineering velocity thrives, sell where demand is loud and fragmented. Pre-orders are live, with a U.S. and India launch lined up for April 2026, and the device sits in that interesting gray zone as a non-medical consumer product, which means speed to market without waiting in regulatory purgatory.

The takeaway here is not just about capital. It is about sequencing. Start with a real problem, validate it with real users, anchor it in credible science, then raise from people who understand both ambition and restraint. Mave is not selling a miracle. They are selling consistency, 20 minutes at a time, in a world addicted to shortcuts.

And that is where it gets interesting. Because if attention becomes programmable and stress becomes manageable on demand, the question is no longer whether people will adopt tools like this, it is how quickly they start treating mental performance like a daily KPI.